GT Biopharma, Inc.
GTBPNASDAQHealthcare● Active
$0.43
$-0.01(-2.57%)
Market Cap$4516410
P/E Ratio—
52W High$3.85
52W Low$0.261
GT Biopharma, Inc.（GTBP）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · GTBP · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.01B | $0.01B | $0.01B | $0.01B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.05B |
| Total Operating Expenses | $0.01B | $0.01B | $0.01B | $0.02B | $0.06B |
| Operating Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.06B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.03B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.06B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.03B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.06B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-6.25 | $-6.94 | $-5.64 | $-0.66 | $-2.06 |
| Wtd Avg Shares | 0.01B | 0.00B | 0.00B | 0.03B | 0.03B |
| EBITDA | ($0.01B) | ($0.01B) | $0.01B | ($0.02B) | ($0.06B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · B
深入了解GT Biopharma, Inc.
关于GT Biopharma, Inc.（GTBP）损益表
GT Biopharma, Inc.（GTBP）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，GTBP实现营收$0.00B，毛利润$0.00B（毛利率—），净利润($0.03B)（净利率—）。
常见问题
GTBP · 4 问GT Biopharma, Inc.（GTBP）2025财年营收为$0.00B，同比down—%。
GTBP revenueGTBP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09